Abstract
Background: The impact on survival by components of a surveillance program (physical examination, blood tests, and chest radiograph) used to detect recurrences in patients with cutaneous melanoma was assessed.
Methods: Data were collected from medical records and tumor registry information on a historical cohort of 1004 patients who presented with AJCC Stage I or II cutaneous melanoma at Roswell Park Cancer Institute from 1971 through 1995.
Results: Information on method of detection was available on 154 out of 174 identified first recurrences (89%). Physical examination detected 72% of recurrences, constitutional symptoms indicated 17% of recurrences, and chest radiograph revealed 11% of recurrences. Blood tests did not predict any recurrence. Only 9 of 17 patients with recurrences detected by chest radiograph alone underwent curative surgical resection. These patients had a statistically significant prolonged survival after diagnosis of recurrence compared to those surgical candidates who did not undergo resection. There was no statistically significant difference in overall survival between patients with asymptomatic pulmonary recurrences and those whose pulmonary recurrences were detected after symptoms of metastatic disease had developed.
Conclusions: Most recurrences are detected on physical examination. Blood tests have no role in surveillance programs. Chest radiographs can detect pulmonary recurrences in a small number of asymptomatic patients at a stage when surgery may prolong survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society.Cancer Facts and Figures—1974. New York: American Cancer Society, 1974.
American Cancer Society.Cancer Facts and Figures—1997. Atlanta: American Cancer Society, 1997.
Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds.SEER Cancer Statistics Review, 1973–1992: Tables and Graphs. NIH Pub. No. 96-2789. Bethesda, MD: National Cancer Institute, 1995. (CD-ROM Public Access File).
Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients.Ann Surg 1990;212:173–7.
Tahery DP, Moy RL. Recurrent malignant melanoma following a 35-year disease-free interval.J Dermatol Surg Oncol 1993;19:161–3.
Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma.J Dermatol Surg Oncol 1994;20:175–8.
Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.JAMA 1995;274:1703–5.
Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10-year experience in a dermatology department in France.Dermatology 1995;191:199–203.
Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds.Manual for staging of cancer, 4th ed. Philadelphia: JB Lippincott, 1992:143–5.
Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis.Cancer 1997;80:1052–64.
Armstrong P. Neoplasms of the lungs, airways, and pleura. In: Armstrong P, Wilson AG, Dee P, Hansell DM, eds.Imaging of diseases of the chest, 2nd ed. St. Louis: Mosby, 1995;272–368.
Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance: patient or physician based?Ann Surg 1995;221:566–71.
Ruark DS, Shaw HM, Ingvar C, McCarthy WH, Thompson JF. Who detects the first recurrence in stage I cutaneous malignant melanoma: patient or doctor? Abstract from the Third International Conference on Melanoma.Melanoma Research 1993;3:44.
Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience.Ann Thorac Surg 1984;38:323–30.
Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung.Surgery 1990;107:256–61.
Harpole DH, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma.J Thorac Cardiovasc Surg 1992;103:743–50.
Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung.Arch Surg 1988;123:1091–5.
Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax.J Thorac Cardiovasc Surg 1995;110:119–29.
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial.JAMA 1994;271:1587–92.
Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial.JAMA 1994;271:1593–7.
Soong S-J, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach.World J Surg 1992;16:191–5.
Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression: implications for the concept of cure.Cancer 1992;70:1917–27.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mooney, M.M., Kulas, M., McKinley, B. et al. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Annals of Surgical Oncology 5, 54–63 (1998). https://doi.org/10.1007/BF02303765
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303765